Previous 10 | Next 10 |
home / stock / mrvl / mrvl articles
Two technology sector AI plays — Arista Networks Inc (NYSE:ANET) and Globalfoundries Inc (NASDAQ:GFS) — will be reporting their first-quarter e...
Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 20 years by 1.99% on an annualized basis producing an average annual return of...
Microsoft Corp (NASDAQ:MSFT), Meta Platforms Inc (NASDAQ:META), and Google parent Alphabet Inc (NASDAQ:GOOG) (NA...
Evercore ISI Group analyst Mark Lipacis initiated coverage on Marvell Technology Inc (NASDAQ:MRVL) with an Outperform rating and a&n...
Marvell Tech (NASDAQ:MRVL) has outperformed the market over the past 15 years by 1.17% on an annualized basis producing an average annual return of...
Needham analyst Quinn Bolton reiterated a Buy rating on Marvell Technology Inc (NASDAQ:MRVL) with a price target of $95. On Thu...
The semiconductor industry continues to navigate the complex geopolitical landscape, with U.S. companies maintaining a significant presence in the ...
Following KeyBanc Capital Markets‘ quarterly supply-chain findings, the firm’s semiconductor analyst John Vinh revisited his estimates ...
BofA Securities analyst Vivek Arya reiterated a Buy rating on Marvell Technology, Inc. (NASDAQ:MRVL) with a price forecast of $...
News, Short Squeeze, Breakout and More Instantly...
Marvell Technology Inc. Company Name:
MRVL Stock Symbol:
NASDAQ Market:
Marvell Technology Inc. Website:
Calgary, Alberta--(Newsfile Corp. - July 19, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the " Company " or " Marvel "), is pleased to report that, further to its press releases of May 16, 2024 and June 21, 2024, it has ...
2024-07-15 18:00:00 ET Broadcom (NASDAQ: AVGO) and Marvell Technology (NASDAQ: MRVL) usually don't attract as much attention as higher-growth chipmakers like Nvidia (NASDAQ: NVDA) . But like Nvidia, both diversified chip specialists are benefiting from the rapid ...
Calgary, Alberta--(Newsfile Corp. - July 9, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to highlight the recently published paper "Neuronal A2A receptor exacerbate...